Abstract
Insulin resistance has been associated with the development of type 2 diabetes, obesity, hypertension, dyslipidemia, atherosclerosis, and thus with increased cardiovascular morbidity and mortality. Insulin resistance precedes the onset of type 2 diabetes by many years. Targeting the pathophysiologic defects that characterize the onset of diabetes is more likely to achieve a durable glucose control and to delay disease progression. Incretins are gut-derived peptides that stimulate in a glucose-dependent mechanism insulin secretion and action. Glucose-like peptide 1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors both decrease fasting and postprandial glucose levels. In addition, GLP-1 analogues promote weight loss and exert a favorable effect on several cardiovascular risk factors. Data from human and experimental studies implicate that GLP-1 analogues and to a less extend DPP-4 inhibitors enhance insulin sensitivity. This review summarizes the current knowledge regarding the impact of GLP-1 analogues and DPP-4 inhibitors on insulin resistance.
Keywords: DPP-4 inhibitors, GLP-1 analogues, insulin resistance, type 2 diabetes.
Current Diabetes Reviews
Title:Incretin-based Therapies for Type 2 Diabetes Mellitus: Effects on Insulin Resistance
Volume: 9 Issue: 5
Author(s): Pinelopi Grigoropoulou, Ioanna Eleftheriadou, Christos Zoupas, Evanthia Diamanti-Kandarakis and Nicholas Tentolouris
Affiliation:
Keywords: DPP-4 inhibitors, GLP-1 analogues, insulin resistance, type 2 diabetes.
Abstract: Insulin resistance has been associated with the development of type 2 diabetes, obesity, hypertension, dyslipidemia, atherosclerosis, and thus with increased cardiovascular morbidity and mortality. Insulin resistance precedes the onset of type 2 diabetes by many years. Targeting the pathophysiologic defects that characterize the onset of diabetes is more likely to achieve a durable glucose control and to delay disease progression. Incretins are gut-derived peptides that stimulate in a glucose-dependent mechanism insulin secretion and action. Glucose-like peptide 1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors both decrease fasting and postprandial glucose levels. In addition, GLP-1 analogues promote weight loss and exert a favorable effect on several cardiovascular risk factors. Data from human and experimental studies implicate that GLP-1 analogues and to a less extend DPP-4 inhibitors enhance insulin sensitivity. This review summarizes the current knowledge regarding the impact of GLP-1 analogues and DPP-4 inhibitors on insulin resistance.
Export Options
About this article
Cite this article as:
Grigoropoulou Pinelopi, Eleftheriadou Ioanna, Zoupas Christos, Diamanti-Kandarakis Evanthia and Tentolouris Nicholas, Incretin-based Therapies for Type 2 Diabetes Mellitus: Effects on Insulin Resistance, Current Diabetes Reviews 2013; 9 (5) . https://dx.doi.org/10.2174/15733998113099990070
DOI https://dx.doi.org/10.2174/15733998113099990070 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
L-4F Differentially Alters Plasma Levels of Oxidized Fatty Acids Resulting in more Anti-Inflammatory HDL in Mice
Drug Metabolism Letters Pathogenesis-Oriented Targets for Adjunctive Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Pro-Inflammatory Mechanisms in Diabetic Neuropathy: Focus on the Nuclear Factor Kappa B Pathway
Current Drug Targets Influences of Maternal Nutritional Status on Vascular Function in the Offspring
Current Drug Targets ATP-Sensitive Potassium Channels
Current Pharmaceutical Design Pathogenesis of Acute Kidney Injury During Sepsis
Current Drug Targets Diabetic CVD – Focus on Vitamin D
Cardiovascular & Hematological Agents in Medicinal Chemistry An Efficient One-Pot Organocatalyzed Synthesis of Spiro[Chroman-3,6'- Furo[2,3-d]Pyrimidine]-Tetraones
Combinatorial Chemistry & High Throughput Screening Towards Optimal Heart Failure Care: Couples-Oriented Strategies to Improve Patient Adherence and Health Outcomes
Current Cardiology Reviews Counter-regulatory ‘Renin-Angiotensin’ System-based Candidate Drugs to Treat COVID-19 Diseases in SARS-CoV-2-infected Patients
Infectious Disorders - Drug Targets Ezetimibe and Vascular Inflammation
Current Vascular Pharmacology Interstitial Lung Disease Associated with Polymyositis-Dermatomyositis
Current Respiratory Medicine Reviews Cilostazol in the Management of Atherosclerosis
Current Vascular Pharmacology Structure-Based Discovery of PDEs Inhibitors
Current Topics in Medicinal Chemistry Curcumin Activates Erythrocyte Membrane Acetylcholinesterase
Letters in Drug Design & Discovery There is a Link Between Erectile Dysfunction and Heart Failure: It could be Inflammation
Current Drug Targets Gender Differences in Ischemic Heart Disease
Recent Patents on Cardiovascular Drug Discovery Thromboxane A<sub>2</sub> Receptor Polymorphism in Association with Cerebral Infarction and its Regulation on Platelet Function
Current Neurovascular Research Antiplatelets and Antithrombotics in Patients with Liver Insufficiency: From Pathophysiology to Clinical Practice
Current Pharmaceutical Design Potential Options to Treat Hypertriglyceridaemia
Current Drug Targets